ClinicalTrials.gg
Not yet recruitingNCT05132543Updated Nov 20, 2026

Neural Basis of Cognition

An interventional study of High density micro-electrocorticography for neural speech prothesis in Epilepsy, sponsored by Duke University. Not yet recruiting. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Duke University · Not applicable, Interventional, and Basic science

How we know

Updated Nov 20, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Study summary

The overall purpose of this study is to better understand human cognition and human epilepsy by working with patients undergoing clinical treatment for pharmacologically resistant epilepsy. The investigators will investigate human cognition by conducting controlled experiments that focus on sensory, motor, and cognitive phenomena such as sensory processing, memory, and language. The investigators will also examine the neural underpinnings of epilepsy during both sleep and wakefulness to better understand both the foundations of epilepsy and how epilepsy affects cognition. The investigators hope to use these data to have a better understanding of cognition, epilepsy, and how the two interact. This will potentially lead to better markers for seizure onsets as well as epilepsy more generally. For this research, the investigators will use μECoG arrays manufactured by commercial partners. These arrays have passed all major ISO 10993 bio-compatibility tests. Based on this characterization and use in the intraoperative setting (limited duration and supervised usage), these devices pose a minimal risk to participants. Data will be analyzed and protected using the Duke SSRI protected research data network.

02

Conditions studied

  • Epilepsy

Browse trials for

03

In context

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

This study's planned enrollment of 38 is below the median of 50 across 1,240 interventional studies indexed under Epilepsy.

Browse Epilepsy studies →

Lead sponsor

Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Potential subjects will come from adult and pediatric patients (between the ages of 12 and 18) undergoing surgery for the treatment of pharmacologically resistant epilepsy, brain tumor resection, brain mass resection, or deep brain stimulation (DBS) for the first time
  • Proficient English speakers
  • No Major cognitive impairment

Exclusion criteria

Exclusion Criteria:

  • Previous DBS procedure
  • Subject unable to consent to study
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Wireless µECoG Prosthesis for Speech

    Device: High density micro-electrocorticography for neural speech prothesis

Interventions

  • DeviceHigh density micro-electrocorticography for neural speech prothesis

    ECoG electrodes are thin, high-density, flexible electrode arrays used for recording electrophysiological signals from the brain.

06

What researchers measure

Primary outcomes

  1. Evoked signal-to-noise analysis human brain.

    This study will compare the neural response sensitivity of intraoperative µECoG recording to those of in-unit recordings with macro-ECoG and SEEG. The strength and reliability of the high gamma (HG) response are critical for speech decoding algorithms. For all recordings, the HG power modulation ratio over baseline during speech perception and production will be measured and compared with non-parametric statistical tests.

    Time frame: Intraoperative data collection period, 20 minutes

  2. Percentage of phoneme decoding accuracy as measured by linear decoding model

    Time frame: Intraoperative data collection period, 20 minutes

  3. Number of HG power modulation as measured by signal power.

    Time frame: Intraoperative data collection period, 20 minutes

  4. Number of kriging resolution as measured by signal power.

    Time frame: Intraoperative data collection period, 20 minutes

Secondary outcomes

  1. Number of serious adverse events as measured by medical record review

    Time frame: Implantation to Three-months follow-up

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Following completion of this project and 8 months after acceptance of the primary manuscript(s), the research data will be made available to the scientific community through public repository for neurophysiological data (e.g. Pennsieve and crcns.org) for both research and educational purposes. Recordings from clinical and research electrodes will be de-identified. The investigators will also include the relevant task data, electrode coordinates in MNI and subject specific space, essential de-identified clinical data using NINDS Common Data Elements (age, sex, duration of epilepsy, epilepsy etiology, preoperative imaging findings), schematics of seizure-onset areas, and any relevant scripts needed to manipulate the data. All data will be reviewed prior to upload to ensure they contain no PHI and will be stripped of voice recordings and be HIPAA compliant.

Supporting information: Informed consent form, Analytic code

Time frame: Following completion of this project and 8 months after acceptance of the primary manuscript(s), the research data will be made available to the scientific community.

Access criteria: DANDI repository

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Sep 2027, 8 months later.

Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's planned 8 months is below that.

Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2021
First posted
Nov 24, 2021
StartEst.
Jan 2027was Sep 2026
Primary completionEst.
Sep 15, 2027
CompletionEst.
Sep 15, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Jan 2027
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Start date Sep 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05132543
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Nov 24, 2021
Start date
Jan 2027 (estimated)
Primary completion
Sep 15, 2027 (estimated)
Completion
Sep 15, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Gregory B Cogan, PhD
Contact
gregory.cogan@duke.edu
919-681-7601
Jessica Carlson
Contact
jessica.carlson@duke.edu
(919)668-2841
Gregory B Cogan, PhD
principal investigator · Duke University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion